Nivolumab Receives New Indication for dMMR and MSI-H Metastatic Colorectal Cancer

JHOP Web Exclusives - FDA News & Updates, Online Only

On July 31, 2017, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of patients aged ≥12 years with mismatch repair–deficient (dMMR) and microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC) that progressed after treatment with fluoropyrimidine, oxaliplatin, and irinotecan.

The FDA approval of this new indication was based on a single-arm, open-label, multicenter clinical trial of 53 patients with locally determined dMMR or MSI-H metastatic CRC whose disease progressed during or after, or who could not tolerate, fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. All patients had received ≥1 treatments containing 1 of the 3 therapies. In the study leading to this approval, the patients received intravenous nivolumab 3 mg/kg every 2 weeks until unacceptable toxicity or radiographic progression.

The objective response rate was 28% (N = 15); of these 15 responses, 1 was a complete response and 14 were partial responses. In 67% of patients, the responses lasted ≥6 months. Among the 74 patients in the overall population, there was an objective response rate of 32%.

The study did not include a pediatric population; nivolumab’s dosing is 240 mg every 2 weeks in patients aged ≥12 years with MSI-H or dMMR metastatic CRC, which was determined based on results in adults.

The most common (≥20%) adverse events seen with nivolumab monotherapy include fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, and pyrexia. As a condition of the accelerated approval of this indication, further trials must confirm the clinical benefit of nivolumab in this setting

Related Items
Actemra First FDA-Approved Treatment for CAR T-Cell–Induced Severe Cytokine Release Syndrome
JHOP Web Exclusives published on October 30, 2017 in FDA News & Updates, Online Only
Mylotarg Now Approved for the Treatment of Patients with CD33-Positive AML
JHOP Web Exclusives published on October 30, 2017 in FDA News & Updates, Online Only
Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL
JHOP Web Exclusives published on October 9, 2017 in FDA News & Updates, Online Only
Kymriah First Gene Therapy Approved by the FDA, Indicated for Young Patients with B-Cell ALL and CD19
JHOP Web Exclusives published on October 9, 2017 in FDA News & Updates, Online Only
Olaparib Tablet Receives New Indication in Ovarian Cancer
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in FDA News & Updates
FDA News - September 2017
JHOP Web Exclusives published on September 8, 2017 in FDA News & Updates, Online Only
FDA News - August 2017
JHOP Web Exclusives published on August 1, 2017 in FDA News & Updates, Online Only
FDA News - June 2017
JHOP Web Exclusives published on June 1, 2017 in FDA News & Updates, Online Only
Cancer Drug Approvals: A Tale of 2 Views
Sharon Donovan
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in FDA News & Updates
FDA News - April 2017: Additional Items
JHOP Web Exclusives published on April 14, 2017 in FDA News & Updates, Online Only
Last modified: October 30, 2017